Organization
Princess Maxima Center for Pediatric Oncology
8 clinical trials
2 abstracts
Abstract
Biological Medicines for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication (BIOMEDE): Final results of an international randomized phase II platform trial comparing 3 targeted therapies in combination with radiotherapy from ITCC, SIOPE-Brain and ANZCHOG.Org: Gustave Roussy Cancer Centre, University College London Hospital NHS Trust and Great Ormond Street Hospital, Department of Women's and Children's Health, Princess Maxima Center, Necker Hospital,
Abstract
Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML).Org: Prinses Maxima Centrum, Pfizer R&D UK Ltd, IRCCS Bambino Gesù Children’s Hospital, Erasmus MC Cancer Institute, Hematologics,
Clinical trial
An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients - a Study by the NOPHO-DB-SHIP Consortium, Master ProtocolStatus: Recruiting, Estimated PCD: 2031-03-01
Clinical trial
A Phase II, Single Arm, Open Label, Study on the Safety, Efficacy, Pharmacokinetics & Pharmacodynamics of Quizartinib + Chemotherapy and as Single-agent After High Dose Therapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML PatientsStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
Interfant-21 International Collaborative Treatment Protocol for Infants Under One Year With KMT2A-rearranged Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia.Status: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-protocol B Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Not yet recruiting, Estimated PCD: 2030-10-01
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol C Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Not yet recruiting, Estimated PCD: 2030-10-01
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Not yet recruiting, Estimated PCD: 2029-10-01
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol D: Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2029-04-01
Clinical trial
Phase Ib Study Combining Dinutuximab Beta With Induction Chemotherapy Regimens in Patients With Newly Diagnosed High-risk NeuroblastomaStatus: Not yet recruiting, Estimated PCD: 2030-07-01